UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients

International Journal of Clinical Oncology

Volumn 14, Issue 2, 2009, Pages 136-142

  Onoue, Masahide ^a   Terada, Tomohiro ^a   Kobayashi, Masahiko ^a   Katsura, Toshiya ^a   Matsumoto, Shigemi ^a   Yanagihara, Kazuhiro ^a   Nishimura, Takafumi ^a   Kanai, Masashi ^a   Teramukai, Satoshi ^a   Shimizu, Akira ^a   Fukushima, Masanori ^a   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Irinotecan; Pharmacogenetics; Polymorphism; SLCO1B1; UGT1A1

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; ORGANIC ANION TRANSPORTER 2; ANTINEOPLASTIC AGENT; BILIRUBIN URIDINE DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; BILIRUBIN URIDINE-DIPHOSPHOGLUCURONOSYL TRANSFERASE 1A1; CAMPTOTHECIN; DRUG DERIVATIVE; GLUCURONOSYLTRANSFERASE; ORGANIC ANION TRANSPORTER; SLCO1B1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; DISEASE SEVERITY; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; INCIDENCE; JAPANESE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STOMACH CANCER; CHEMICALLY INDUCED DISORDER; GENETICS; MIDDLE AGED; NEOPLASM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, GENETIC;

EID: 65349181626     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0821-z     Document Type: Article

References (26)

1. J.A. Meyerhardt R.J. Mayer 2005 Systemic therapy for colorectal cancer N Engl J Med 352 476 487 (Pubitemid 40175989)
2. K. Noda Y. Nishiwaki M. Kawahara 2002 Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 85 91 (Pubitemid 34438898)
3. K.K. Hahn J.J. Wolff J.M. Kolesar 2006 Pharmacogenetics and irinotecan therapy Am J Health Syst Pharm 63 2211 2217
4. F. Innocenti S.D. Undevia L. Iyer 2004 Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22 1382 1388 (Pubitemid 41103619)
5. Y. Ando H. Saka M. Ando 2000 Polymorphisms of UDPglucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Cancer Res 60 6921 6926 (Pubitemid 32059164)
6. R.P. Ramchandani Y. Wang B.P. Booth 2007 The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity J Clin Pharmacol 47 78 86
7. G. Monaghan M. Ryan R. Seddon 1996 Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome Lancet 347 578 581 (Pubitemid 26070740)
8. Y. Ando M. Chida K. Nakayama 1998 The UGT1A1*28 allele is relatively rare in a Japanese population Pharmacogenetics 8 357 360 (Pubitemid 28372330)
9. N. Kaniwa K. Kurose H. Jinno 2005 Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African-American Drug Metab Dispos 33 458 465 (Pubitemid 40279948)
10. K. Sai M. Saeki Y. Saito 2004 UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer Clin Pharmacol Ther 75 501 515 (Pubitemid 38746601)
11. H. Minami K. Sai M. Saeki 2007 Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*l6 and*l28 Pharmacogenet Genomics 17 497 504 (Pubitemid 46905216)
12. K. Araki K. Fujita Y. Ando 2006 Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer Cancer Sci 97 1255 1259 (Pubitemid 44430653)
13. J.Y. Han H.S. Lim E.S. Shin 2006 Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin J Clin Oncol 24 2237 2244 (Pubitemid 46630652)
14. V. Charasson R. Bellott D. Meynard 2004 Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38 Clin Pharmacol Ther 76 528 535 (Pubitemid 39601543)
15. F.A. de Jong T.J. Scott-Horton D.L. Kroetz 2007 Irinotecaninduced diarrhea: functional significance of the polymorphic ABCC2 transporter protein Clin Pharmacol Ther 81 42 49 (Pubitemid 46050866)
16. T. Nozawa H. Minami S. Sugiura 2005 Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms Drug Metab Dispos 33 434 439 (Pubitemid 40279945)
17. X. Xiang S.R. Jada H.H. Li 2006 Pharmacogenetics of SLCO1B1 gene and the impact of1b and15 haplotypes on irinotecan disposition in Asian cancer patients Pharmacogenet Genomics 16 683 691 (Pubitemid 44223079)
18. K. Akaba T. Kimura A. Sasaki 1999 Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese J Hum Genet 44 22 25 (Pubitemid 29058527)
19. Y. Maruo K. Nishizawa H. Sato 1999 Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism Pediatrics 103 1224 1227 (Pubitemid 29258797)
20. J.D. Bancroft B. Kreamer G.R. Gourley 1998 Gilbert syndrome accelerates development of neonatal jaundice J Pediatr 132 656 660 (Pubitemid 28194587)
21. M. Ciotti N. Basu M. Brangi 1999 Glucuronidation of 7-ethyl-10- hydroxycamptothecin (SN-38) by the human UDPglucuronosyltransferases encoded at the UGT1 locus Biochem Biophys Res Commun 260 199 202 (Pubitemid 29351807)
22. J.F. Gagne V. Montminy P. Belanger 2002 Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10- hydroxycamptothecin (SN-38) Mol Pharmacol 62 608 617 (Pubitemid 36329379)
23. K. Fujita Y. Ando F. Nagashima 2007 Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1 6 is associated with reduced activity for SN-38 in Japanese patients with cancer Cancer Chemother Pharmacol 60 515 522 (Pubitemid 47084262)
24. J.M. Hoskins R.M. Godberg P. Qu 2007 UGT1A1*28 genotype and irinotecan-induced neutropenia J Natl Cancer Inst 99 1290 1295
25. Y. Nishizato I. Ieiri H. Suzuki 2003 Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics Clin Pharmacol Ther 73 554 565 (Pubitemid 37249126)
26. T. Tokui D. Nakai R. Nakagomi 1999 Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2 Pharm Res 16 904 908 (Pubitemid 29284203)